{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:24:45Z","timestamp":1792758285814,"version":"4.5.0"},"reference-count":285,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01157","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T03:59:24Z","timestamp":1541476764000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":273,"title":["Anakinra Therapy for Non-cancer Inflammatory Diseases"],"prefix":"10.3389","volume":"9","author":[{"given":"Giulio","family":"Cavalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Dinarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.amjcard.2009.12.059","article-title":"Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).","volume":"105","author":"Abbate","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].","volume":"111","author":"Abbate","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"B3","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/art.10509","article-title":"Association of mutations in the NALP3\/CIAS1\/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis.","volume":"46","author":"Aganna","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1074-7613(04)00046-9","article-title":"NALP3 forms an IL-1beta processing inflammasome with increased activity in muckle-wells auto-inflammatory disorder.","volume":"20","author":"Agostini","year":"2004","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/0194599811402296","article-title":"Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations.","volume":"145","author":"Ahmadi","year":"2011","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"B6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jbspin.2010.04.018","article-title":"Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome.","volume":"77","author":"Ait-Abdesselam","year":"2011","journal-title":"Joint Bone Spine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1056\/NEJMoa0807865","article-title":"An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.","volume":"360","author":"Aksentijevich","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study.","volume":"12","author":"Alten","year":"2011","journal-title":"BMC Musculoskelet. Disord."},{"key":"B9","article-title":"Anti-TNF alpha therapy does not always protect rheumatoid arthritis patients against developing pericarditis.","volume":"25","author":"Ambrose","year":"2007","journal-title":"Clin. Exp. Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamaophthalmol.2013.195","article-title":"Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.","volume":"131","author":"Amparo","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jbspin.2009.01.001","article-title":"Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure.","volume":"76","author":"Announ","year":"2009","journal-title":"Joint Bone Spine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1182\/blood-2010-04-279240","article-title":"Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease.","volume":"116","author":"Aouba","year":"2010","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.4049\/jimmunol.134.6.3868","article-title":"Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor.","volume":"134","author":"Arend","year":"1985","journal-title":"J. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1529-8019.2010.01339.x","article-title":"Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview.","volume":"23","author":"Aronson","year":"2010","journal-title":"Dermatol. Ther."},{"key":"B15","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/art.22966","article-title":"NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort.","volume":"56","author":"Arostegui","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B16","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood.V84.7.2136.2136","article-title":"Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo.","volume":"84","author":"Aukrust","year":"1994","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.1073\/pnas.81.24.7907","article-title":"Nucleotide sequence of human monocyte interleukin 1 precursor cDNA.","volume":"81","author":"Auron","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B18","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.2008.094284","article-title":"Erosive osteoarthritis of the hand: clinical experience with anakinra.","volume":"68","author":"Bacconnier","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"B500","article-title":"Identification of interleukin 1-like activity and inhibitor(s) in urine from a patient with acute monoblastic leukemia.","volume":"3","author":"Balavoine","year":"1984","journal-title":"Lymphokine Res"},{"key":"B501","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1172\/JCI112669","article-title":"Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s).","volume":"78","author":"Balavoine","year":"1986","journal-title":"J. Clin. Invest."},{"key":"B19","doi-asserted-by":"publisher","first-page":"14224","DOI":"10.1074\/jbc.RA118.003698","article-title":"Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue.","volume":"293","author":"Ballak","year":"2018","journal-title":"J. Biol. Chem."},{"key":"B20","first-page":"2081","article-title":"Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis.","volume":"33","author":"Behrens","year":"2006","journal-title":"J. Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamadermatol.2013.2705","article-title":"Neutrophilic urticaria with systemic inflammation: a case series.","volume":"149","author":"Belani","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.autrev.2014.12.005","article-title":"Giant cell arteritis restricted to the limb arteries: an overlooked clinical entity.","volume":"14","author":"Berti","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1318237","article-title":"Tocilizumab in patients with multisystem erdheim-chester disease.","volume":"6","author":"Berti","year":"2017","journal-title":"Oncoimmunology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000814","article-title":"Severe late-onset kawasaki disease successfully treated with anakinra.","author":"Blonz","year":"2018","journal-title":"J. Clin. Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1136\/ard.2011.149922","article-title":"On-demand anakinra treatment is effective in mevalonate kinase deficiency.","volume":"70","author":"Bodar","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/j.celrep.2018.01.063","article-title":"beta cell-specific deletion of the IL-1 receptor antagonist impairs beta cell proliferation and insulin secretion.","volume":"22","author":"Boni-Schnetzler","year":"2018","journal-title":"Cell Rep."},{"key":"B27","first-page":"32","article-title":"Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis.","volume":"59","author":"Botsios","year":"2007","journal-title":"Reumatismo"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-9-21","article-title":"Partial response to anakinra in life-threatening Henoch-Schonlein purpura: case report.","volume":"9","author":"Boyer","year":"2011","journal-title":"Pediatr. Rheumatol. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","article-title":"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome.","volume":"66","author":"Braun-Falco","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","article-title":"Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra.","volume":"161","author":"Brenner","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum."},{"key":"B32","first-page":"1103","article-title":"Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial.","volume":"31","author":"Bresnihan","year":"2004","journal-title":"J. Rheumatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical Trial.","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/eurheartj\/ehy128","article-title":"Interleukin-1 blockade in cardiovascular diseases: a clinical update.","volume":"39","author":"Buckley","year":"2018","journal-title":"Eur. Heart J."},{"key":"B35","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00003246-199907000-00018","article-title":"Tumor necrosis factor-a and interleukin-1b synergistically depress human myocardial function.","volume":"27","author":"Cain","year":"1999","journal-title":"Crit. Care Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ejim.2015.03.004","article-title":"Erdheim-chester disease.","volume":"26","author":"Campochiaro","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/annrheumdis-2013-204924","article-title":"BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.","volume":"74","author":"Cangi","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition.","volume":"139","author":"Canna","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"B39","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1126\/science.3871966","article-title":"Increased plasma interleukin-1 activity in women after ovulation.","volume":"227","author":"Cannon","year":"1985","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet\u2019s disease.","volume":"14","author":"Cantarini","year":"","journal-title":"Autoimmun. Rev."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series.","volume":"34","author":"Cantarini","year":"","journal-title":"Clin. Rheumatol."},{"key":"B42","article-title":"Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment.","volume":"28","author":"Cantarini","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1007\/s00296-010-1512-4","article-title":"Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series.","volume":"32","author":"Cantarini","year":"","journal-title":"Rheumatol. Int."},{"key":"B44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.autrev.2012.07.020","article-title":"Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives.","volume":"12","author":"Cantarini","year":"","journal-title":"Autoimmun. Rev."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203685","article-title":"Diagnosing erdheim-chester disease.","volume":"72","author":"Cavalli","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/annrheumdis-2012-202542","article-title":"The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases.","volume":"72","author":"Cavalli","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00281","article-title":"Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease.","volume":"5","author":"Cavalli","year":"2014","journal-title":"Front. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/21678707.2017.1285226","article-title":"Advances in potential targeted therapies for erdheim-chester disease.","volume":"5","author":"Cavalli","year":"","journal-title":"Expert Opin. Orphan Drugs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00131","article-title":"Interleukin-1 Receptor blockade rescues myocarditis-associated end-stage heart failure.","volume":"8","author":"Cavalli","year":"","journal-title":"Front. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1073\/pnas.1619011114","article-title":"Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance.","volume":"114","author":"Cavalli","year":"","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/rheumatology\/kex348","article-title":"Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation.","volume":"56","author":"Cavalli","year":"","journal-title":"Rheumatology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1093\/rheumatology\/kev269","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.","volume":"54","author":"Cavalli","year":"2015","journal-title":"Rheumatology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by IL-37.","volume":"281","author":"Cavalli","year":"2018","journal-title":"Immunol. Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1164\/rccm.201412-2150LE","article-title":"Treating pulmonary silicosis by blocking interleukin 1.","volume":"191","author":"Cavalli","year":"","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still\u2019s disease.","volume":"44","author":"Cavalli","year":"","journal-title":"Scand. J. Rheumatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1073\/pnas.1523482113","article-title":"MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo.","volume":"113","author":"Cavalli","year":"","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/rheumatology\/kew325","article-title":"Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation.","volume":"55","author":"Cavalli","year":"","journal-title":"Rheumatology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1097\/CCM.0000000000001654","article-title":"Treating life-threatening myocarditis by blocking interleukin-1.","volume":"44","author":"Cavalli","year":"","journal-title":"Crit. Care Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijcard.2017.10.067","article-title":"Prevalence of Takayasu arteritis in young women with acute ischemic heart disease.","volume":"252","author":"Cavalli","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.2337\/dc11-2219","article-title":"Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes.","volume":"35","author":"Cavelti-Weder","year":"2012","journal-title":"Diabetes Care"},{"key":"B61","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.1073\/pnas.0602081103","article-title":"The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production.","volume":"103","author":"Chae","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B62","first-page":"1317","article-title":"Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study.","volume":"32","author":"Chevalier","year":"2005","journal-title":"J. Rheumatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/art.24096","article-title":"Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study.","volume":"61","author":"Chevalier","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B64","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00415-017-8692-8","article-title":"Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease.","volume":"265","author":"Chiapparini","year":"2018","journal-title":"J. Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1365-2133.2010.10137.x","article-title":"Clinical experience of QuantiFERON((R)) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.","volume":"164","author":"Chiu","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/j.ijcard.2013.12.151","article-title":"Cardiac magnetic resonance in myocarditis from adult onset Still\u2019s disease successfully treated with anakinra.","volume":"172","author":"Choi","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/jcla.20374","article-title":"Interleukin (IL)-1beta, IL-1 receptor antagonist, IL-6, IL-8, IL-10, and tumor necrosis factor alpha gene polymorphisms in patients with febrile seizures.","volume":"24","author":"Chou","year":"2010","journal-title":"J. Clin. Lab. Anal."},{"key":"B68","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.jcbfm.9600537","article-title":"Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations.","volume":"28","author":"Clark","year":"2008","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B69","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1136\/annrheumdis-2012-201658","article-title":"A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation.","volume":"71","author":"Cohen","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/ar3430","article-title":"A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL 1R1) in patients with osteoarthritis of the knee.","volume":"13","author":"Cohen","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00369","article-title":"Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still\u2019s disease: a multicentre retrospective observational study.","volume":"8","author":"Colafrancesco","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B73","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/rheumatology\/keq074","article-title":"Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra.","volume":"49","author":"Colina","year":"2010","journal-title":"Rheumatology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1136\/annrheumdis-2012-202192","article-title":"Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler\u2019s syndrome.","volume":"72","author":"de Koning","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jaci.2014.07.050","article-title":"Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome.","volume":"135","author":"de Koning","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7326\/L18-0315","article-title":"Treatment of dilated cardiomyopathy with interleukin-1 inhibition.","author":"De Luca","year":"","journal-title":"Ann Intern. Med."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01335","article-title":"Myocarditis: an interleukin-1-mediated disease?","volume":"9","author":"De Luca","year":"","journal-title":"Front. Immunol."},{"key":"B78","article-title":"Assessing the role of pentraxin-3 in Takayasu\u2019s arteritis. comment on: plasma pentraxin-3 levels in patients with takayasu\u2019s arteritis during routine follow-up. Alibaz-Oner F. et al.","volume":"103","author":"De Luca","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"B79","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/ard.2006.068254","article-title":"Efficacy of anakinra, an IL1 receptor antagonist, in refractory sweet syndrome.","volume":"67","author":"Delluc","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1063-2","article-title":"Systemic autoinflammation with intractable epilepsy managed with interleukin-1 blockade.","volume":"15","author":"DeSena","year":"2018","journal-title":"J Neuroinflammation"},{"key":"B81","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.crohns.2012.02.016","article-title":"A rare case of pericarditis, complication of infliximab treatment for Crohn\u2019s disease.","volume":"6","author":"Devasahayam","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1182\/blood-2016-06-725143","article-title":"Anakinra as efficacious therapy for two cases of intracranial Erdheim-Chester disease.","volume":"128","author":"Diamond","year":"2016","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","article-title":"Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.","volume":"124","author":"Diamond","year":"2014","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/rheumatology\/keh479","article-title":"Anakinra for flares of pyogenic arthritis in PAPA syndrome.","volume":"44","author":"Dierselhuis","year":"2005","journal-title":"Rheumatology"},{"key":"B85","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biological basis for interleukin-1 in disease.","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/23328940.2015.1017086","article-title":"The history of fever, leukocytic pyrogen and interleukin-1.","volume":"2","author":"Dinarello","year":"2015","journal-title":"Temperature"},{"key":"B87","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1084\/jem.139.6.1369","article-title":"Demonstration and characterization of two distinct human leukocytic pyrogens.","volume":"139","author":"Dinarello","year":"1974","journal-title":"J. Exp. Med."},{"key":"B88","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.4049\/jimmunol.139.6.1902","article-title":"Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro.","volume":"139","author":"Dinarello","year":"1987","journal-title":"J. Immunol."},{"key":"B89","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1073\/pnas.74.10.4624","article-title":"Human leukocytic pyrogen: purification and development of a radioimmunoassay.","volume":"74","author":"Dinarello","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B90","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.4049\/jimmunol.127.6.2517","article-title":"Demonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans.","volume":"127","author":"Dinarello","year":"1981","journal-title":"J. Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B92","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease.","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00163","article-title":"IL-1 inhibition may have an important role in treating refractory Kawasaki disease.","volume":"8","author":"Dusser","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B95","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/343341a0","article-title":"Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist.","volume":"343","author":"Eisenberg","year":"1990","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/rheumatology\/keq122","article-title":"Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood.","volume":"49","author":"Eleftheriou","year":"2011","journal-title":"Rheumatology"},{"key":"B97","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4414\/smw.2002.09941","article-title":"Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation.","volume":"132","author":"Emmenegger","year":"2002","journal-title":"Swiss Med. Wkly."},{"key":"B98","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/jnnp.2004.054882","article-title":"A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients.","volume":"76","author":"Emsley","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B99","article-title":"Muckle-wells treatment with anakinra.","volume":"19","author":"Eungdamrong","year":"2013","journal-title":"Dermatol. J."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","article-title":"Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes.","volume":"71","author":"Everett","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1181244","article-title":"Plasma chromogranin a as a marker of cardiovascular involvement in Erdheim-Chester disease.","volume":"5","author":"Ferrero","year":"2016","journal-title":"Oncoimmunology"},{"key":"B102","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/art.21061","article-title":"Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease.","volume":"52","author":"Fitzgerald","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B103","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial.","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B104","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis.","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"B105","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3109\/0284186X.2015.1120885","article-title":"Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in erdheim-chester disease: towards the paradigm of combined targeting and immune therapies.","volume":"55","author":"Franconieri","year":"2016","journal-title":"Acta Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/jcbfm.2010.103","article-title":"Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study.","volume":"31","author":"Galea","year":"2011","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B107","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/MPH.0b013e31818ab31f","article-title":"IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease.","volume":"30","author":"Galeotti","year":"2008","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/ped.13614","article-title":"Kawasaki disease shock syndrome; a unique and severe subtype of kawasaki disease.","volume":"60","author":"Gamez-Gonzalez","year":"2018","journal-title":"Pediatr. Int."},{"key":"B109","doi-asserted-by":"crossref","first-page":"R702","DOI":"10.1152\/ajpregu.00393.2001","article-title":"Effect of interleukin-18 on mouse core body temperature.","volume":"282","author":"Gatti","year":"2002","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/art.23475","article-title":"Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome.","volume":"58","author":"Gattorno","year":"","journal-title":"Arthritis Rheum."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.","volume":"58","author":"Gattorno","year":"","journal-title":"Arthritis Rheum."},{"key":"B112","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/art.22842","article-title":"Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations.","volume":"56","author":"Gattorno","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B113","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2001.1196","article-title":"Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the secon 6 months of treatment for patients with rheumatoid arthritis.","author":"Genant","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.01.032","article-title":"Lasting remission of a Muckle-Wells syndrome with CIAS-1 mutation using half-dose anakinra.","volume":"74","author":"Gerard","year":"2007","journal-title":"Joint Bone Spine"},{"key":"B115","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset still\u2019s disease.","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"B116","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11926-011-0165-y","article-title":"Current status of understanding the pathogenesis and management of patients with NOMID\/CINCA.","volume":"13","author":"Goldbach-Mansky","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"key":"B117","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","article-title":"Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.","volume":"355","author":"Goldbach-Mansky","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B118","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/0140-6736(91)92725-H","article-title":"Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans.","volume":"338","author":"Granowitz","year":"1991","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of mucocutaneous manifestations in Behcet\u2019s disease with anakinra: a pilot open-label study.","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"B120","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00002281-200309000-00011","article-title":"Macrophage activation syndrome and reactive hemophagocytic lymphohistiocytosis: the same entities?","volume":"15","author":"Grom","year":"2003","journal-title":"Curr. Opin. Rheumatol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/01.bor.0000381996.69261.71","article-title":"Macrophage activation syndrome: advances towards understanding pathogenesis.","volume":"22","author":"Grom","year":"2011","journal-title":"Curr. Opin. Rheumatol."},{"key":"B122","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1067\/mpd.2003.110","article-title":"Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome.","volume":"142","author":"Grom","year":"2003","journal-title":"J. Pediatr."},{"key":"B123","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.immuni.2011.02.006","article-title":"Type I interferon inhibits interleukin-1 production and inflammasome activation.","volume":"34","author":"Guarda","year":"2011","journal-title":"Immunity"},{"key":"B124","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: an open-label pilot study.","volume":"71","author":"Gul","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B125","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/343336a0","article-title":"Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.","volume":"343","author":"Hannum","year":"1990","journal-title":"Nature"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86336","article-title":"Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology.","volume":"1","author":"Harrison","year":"2016","journal-title":"JCI Insight"},{"key":"B127","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/08830738050200070401","article-title":"Interleukin-1alpha, interleukin-1beta, and interleukin-1Ra polymorphisms in febrile seizures.","volume":"20","author":"Haspolat","year":"2005","journal-title":"J. Child Neurol."},{"key":"B128","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","article-title":"Interleukin-1 receptor antagonist in the Muckle-Wells syndrome.","volume":"348","author":"Hawkins","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1073\/pnas.1525001113","article-title":"Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A\u221702:01 in vivo.","volume":"113","author":"Hayashi","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B130","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.braindev.2008.11.013","article-title":"The role of interleukin-1beta in febrile seizures.","volume":"31","author":"Heida","year":"2009","journal-title":"Brain Dev."},{"key":"B131","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/03009740801978889","article-title":"Good response to IL-1\u03b2 blockade by anakinra in a 23-year-old CINCA\/NOMID patient without mutations in the CIAS1 gene. Cytokine profiles and functional studies.","volume":"37","author":"Hedrich","year":"2008","journal-title":"Scand. J. Rheumatol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/jcbfm.2014.23","article-title":"Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial.","volume":"34","author":"Helmy","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00296-010-1429-y","article-title":"Pneumonia in a patient with familial mediterranean fever successfully treated with anakinra-case report and review.","volume":"32","author":"Hennig","year":"2010","journal-title":"Rheumatol. Int."},{"key":"B134","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/annrheumdis-2012-201818","article-title":"Efficacy of anti-IL-1 treatment in Majeed syndrome.","volume":"72","author":"Herlin","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B135","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/rheumatology\/keh058","article-title":"Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.","volume":"43","author":"Hernandez-Rodriguez","year":"2004","journal-title":"Rheumatology"},{"key":"B136","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/epi.14016","article-title":"Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions.","volume":"59","author":"Hirsch","year":"2018","journal-title":"Epilepsia"},{"key":"B137","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11882-010-0109-z","article-title":"Inflammasome and IL-1beta-mediated disorders.","volume":"10","author":"Hoffman","year":"2011","journal-title":"Curr. Allergy Asthma Rep."},{"key":"B138","first-page":"55","article-title":"Neuron-specific enolase in hemophagocytic lymphohistiocytosis: a potential indicator for macrophage activation?","volume":"72","author":"Honda","year":"2000","journal-title":"Int. J. Hematol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/ni.1631","article-title":"Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.","volume":"9","author":"Hornung","year":"2008","journal-title":"Nat. Immunol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/archdermatol.2010.328","article-title":"Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review.","volume":"146","author":"Hsiao","year":"2011","journal-title":"Arch. Dermatol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3899\/jrheum.161354","article-title":"Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset still disease.","volume":"44","author":"Hsieh","year":"2017","journal-title":"J. Rheumatol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1161\/CIRCULATIONAHA.107.731877","article-title":"Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis.","volume":"117","author":"Ikonomidis","year":"2008","journal-title":"Circulation"},{"key":"B143","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin. Rheumatol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1586\/1744666X.2014.965150","article-title":"Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options.","volume":"10","author":"Imazio","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003697","article-title":"Erdheim-chester disease with multiorgan involvement, following polycythemia vera: a case report.","volume":"95","author":"Iurlo","year":"2016","journal-title":"Medicine"},{"key":"B146","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis.","volume":"63","author":"Janka","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"B147","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/art.30378","article-title":"Role of interleukin-1 in NLRP12-associated autoinflammatory disorders and resistance to anti\u2013. (Interleukin)-1 therapy.","volume":"63","author":"Jeru","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B148","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1002\/art.25006","article-title":"Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta.","volume":"60","author":"Joosten","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B149","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1002\/art.27667","article-title":"Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC\/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis.","volume":"62","author":"Joosten","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B150","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","article-title":"Adult onset Still\u2019s disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review).","volume":"47","author":"Junge","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"B151","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2006.11.026","article-title":"Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism.","volume":"195","author":"Kamari","year":"2007","journal-title":"Atherosclerosis"},{"key":"B152","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/1531-8249(200005)47:5<571::AID-ANA3>3.0.CO;2-A","article-title":"Interleukin (IL)1beta, IL-1alpha, and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy.","volume":"47","author":"Kanemoto","year":"2000","journal-title":"Ann. Neurol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/ncprheum0919","article-title":"A case of macrophage activation syndrome successfully treated with anakinra.","volume":"4","author":"Kelly","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/rheumatology\/kel332","article-title":"What kills patients with rheumatoid arthritis?","volume":"46","author":"Kelly","year":"2007","journal-title":"Rheumatology"},{"key":"B155","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/ana.24806","article-title":"Febrile infection-related epilepsy syndrome treated with anakinra.","volume":"80","author":"Kenney-Jung","year":"2016","journal-title":"Ann. Neurol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/j.ijcard.2013.04.057","article-title":"Erdheim-chester disease with cardiac involvement successfully treated with anakinra.","volume":"167","author":"Killu","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1212\/WNL.0b013e3181d9ed69","article-title":"Neurologic manifestations of the cryopyrin-associated periodic syndrome.","volume":"74","author":"Kitley","year":"2010","journal-title":"Neurology"},{"key":"B158","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1055\/s-0029-1239527","article-title":"Improvement of sensoneurinal hearing loss in a patient with muckle-wells syndrome treated with anakinra.","volume":"222","author":"Klein","year":"2011","journal-title":"Klin. Padiatr."},{"key":"B159","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000326112","article-title":"Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret(R)) in a case of refractory Sweet\u2019s syndrome.","volume":"222","author":"Kluger","year":"2011","journal-title":"Dermatology"},{"key":"B160","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.autrev.2018.01.024","article-title":"The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series.","volume":"17","author":"Kone-Paut","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"B161","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.","volume":"70","author":"Kuemmerle-Deschner","year":"","journal-title":"Ann. Rheum. Dis."},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1186\/ar3526","article-title":"NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment.","volume":"13","author":"Kuemmerle-Deschner","year":"","journal-title":"Arthritis Res. Ther."},{"key":"B163","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/art.30149","article-title":"Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome.","volume":"63","author":"Kuemmerle-Deschner","year":"","journal-title":"Arthritis Rheum."},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1186\/ar4237","article-title":"Treatment of Muckle-wells syndrome: analysis of two IL-1-blocking regimens.","volume":"15","author":"Kuemmerle-Deschner","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","article-title":"Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes.","volume":"55","author":"Kullenberg","year":"2016","journal-title":"Rheumatology"},{"key":"B166","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12288-013-0299-3","article-title":"Macrophage activation syndrome secondary to human monocytic ehrlichiosis.","author":"Kumar","year":"2014","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"B167","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome.","volume":"360","author":"Lachmann","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B168","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1568-9972(03)00091-0","article-title":"Pathogenesis of hemophagocytic syndrome (HPS).","volume":"3","author":"Larroche","year":"2004","journal-title":"Autoimmun. Rev."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2337\/dc09-0533","article-title":"Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.","volume":"32","author":"Larsen","year":"2009","journal-title":"Diabetes Care"},{"key":"B170","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus.","volume":"356","author":"Larsen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B171","doi-asserted-by":"crossref","first-page":"8815","DOI":"10.1073\/pnas.0402800101","article-title":"Differences in signaling pathways by IL-1beta and IL-18.","volume":"101","author":"Lee","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B172","first-page":"e1","article-title":"Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra.","volume":"157","author":"Lepore","year":"2011","journal-title":"J. Pediatr."},{"key":"B173","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(12)60235-9","article-title":"Silicosis.","volume":"379","author":"Leung","year":"2012","journal-title":"Lancet"},{"key":"B174","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis.","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"B175","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000280436","article-title":"Anakinra for difficult-to-treat neutrophilic panniculitis: IL-1 blockade as a promising treatment option for neutrophil-mediated inflammatory skin disease.","volume":"220","author":"Lipsker","year":"2010","journal-title":"Dermatology"},{"key":"B176","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/312458a0","article-title":"Cloning and expression of murine interleukin-1 cDNA in Escherichia coli.","volume":"312","author":"Lomedico","year":"1984","journal-title":"Nature"},{"key":"B177","first-page":"531","article-title":"Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.","volume":"34","author":"Lopalco","year":"","journal-title":"Clin. Exp. Rheumatol."},{"key":"B178","article-title":"Anakinra long-term efficacy and safety in the management of Schnitzler\u2019s syndrome and latent tuberculosis infection.","volume":"34","author":"Lopalco","year":"","journal-title":"Clin. Exp. Rheumatol."},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00181","article-title":"Opposing functions of classic and novel il-1 family members in gut health and disease.","volume":"4","author":"Lopetuso","year":"2013","journal-title":"Front. Immunol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jbspin.2013.06.004","article-title":"Interleukin-1 blockade in refractory giant cell arteritis.","volume":"81","author":"Ly","year":"2013","journal-title":"Joint Bone Spine"},{"key":"B181","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1172\/JCI200215318","article-title":"Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.","volume":"110","author":"Maedler","year":"2002","journal-title":"J. Clin. Invest."},{"key":"B182","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/art.20268","article-title":"Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome.","volume":"50","author":"Maeno","year":"2004","journal-title":"Arthritis Rheum."},{"key":"B183","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.nbd.2008.10.002","article-title":"Antagonism of peripheral inflammation reduces the severity of status epilepticus.","volume":"33","author":"Marchi","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"B184","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","article-title":"The inflammasomes: guardians of the body.","volume":"27","author":"Martinon","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12016-012-8351-x","article-title":"Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and sweet\u2019s syndrome: a comprehensive review and disease classification criteria.","volume":"45","author":"Marzano","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes.","volume":"11","author":"Masters","year":"2010","journal-title":"Nat. Immunol."},{"key":"B187","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","article-title":"Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome.","volume":"106","author":"Mazodier","year":"2005","journal-title":"Blood"},{"key":"B188","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","article-title":"Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.","volume":"97","author":"McDermott","year":"1999","journal-title":"Cell"},{"key":"B189","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/art.23119","article-title":"Successful treatment of resistant pseudogout with anakinra.","volume":"58","author":"McGonagle","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B190","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1136\/ard.2007.073759","article-title":"Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra.","volume":"66","author":"McGonagle","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"B191","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.semarthrit.2010.11.003","article-title":"Interleukin-1 targeting drugs in familial mediterranean fever: a case series and a review of the literature.","volume":"41","author":"Meinzer","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005121.pub3","article-title":"Anakinra for rheumatoid arthritis.","volume":"21","author":"Mertens","year":"","journal-title":"Cochrane Database Syst. Rev."},{"key":"B193","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for rheumatoid arthritis: a systematic review.","volume":"36","author":"Mertens","year":"","journal-title":"J. Rheumatol."},{"key":"B194","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.","volume":"50","author":"Miettunen","year":"2012","journal-title":"Rheumatology"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/S0140-6736(13)60023-9","article-title":"Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.","volume":"381","author":"Moran","year":"2013","journal-title":"Lancet"},{"key":"B196","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.","volume":"36","author":"Morton","year":"2015","journal-title":"Eur. Heart J."},{"key":"B197","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/ndt\/gfn646","article-title":"Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation.","volume":"24","author":"Moser","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"B198","first-page":"623","article-title":"Anakinra for myocarditis in juvenile idiopathic arthritis.","volume":"40","author":"Movva","year":"2013","journal-title":"Tex. Heart Inst. J."},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00342","article-title":"Peri- and postoperative treatment with the interleukin-1 receptor antagonist anakinra is safe in patients undergoing renal transplantation: case series and review of the literature.","volume":"8","author":"Mulders-Manders","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B200","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/IAI.34.1.177-183.1981","article-title":"Rabbit macrophages secrete two biochemically and immunologically distinct endogenous pyrogens.","volume":"34","author":"Murphy","year":"1981","journal-title":"Infect. Immun."},{"key":"B201","doi-asserted-by":"publisher","first-page":"S190","DOI":"10.1016\/j.eplepsyres.2005.11.023","article-title":"Molecular genetics of febrile seizures.","author":"Nakayama","year":"2006","journal-title":"Epilepsy Res."},{"key":"B202","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/ard.2009.108068","article-title":"IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still\u2019s disease.","volume":"69","author":"Naumann","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"B203","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/ni.3790","article-title":"A guiding map for inflammation.","volume":"18","author":"Netea","year":"2017","journal-title":"Nat. Immunol."},{"key":"B204","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.25057","article-title":"Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome.","volume":"62","author":"Neven","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B205","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.1944","article-title":"IL-37 is a fundamental inhibitor of innate immunity.","volume":"11","author":"Nold","year":"2010","journal-title":"Nat. Immunol."},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary Sjogren\u2019s syndrome - a double blind, randomised clinical trial.","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"B207","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/cyto.2001.0914","article-title":"A novel IL-18BP ELISA shows elevated serum il-18BP in sepsis and extensive decrease of free IL-18.","volume":"14","author":"Novick","year":"2001","journal-title":"Cytokine"},{"key":"B208","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4049\/jimmunol.156.1.389","article-title":"IL-1 beta does not cause neutrophil degranulation but does lead to IL- 6, IL-8, and nitrite\/nitrate release when used in patients with cancer.","volume":"156","author":"Ogilvie","year":"1996","journal-title":"J. Immunol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/art.22644","article-title":"Specific gene expression profiles in systemic juvenile idiopathic arthritis.","volume":"56","author":"Ogilvie","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10928-015-9450-0","article-title":"Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist.","volume":"43","author":"Ogungbenro","year":"2016","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B211","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3899\/jrheum.100718","article-title":"Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine.","volume":"38","author":"Ozen","year":"2011","journal-title":"J. Rheumatol."},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1440929","article-title":"The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease.","volume":"7","author":"Pacini","year":"2018","journal-title":"Oncoimmunology"},{"key":"B213","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.","volume":"201","author":"Pascual","year":"2005","journal-title":"J. Exp. Med."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.4049\/jimmunol.1002275","article-title":"IL-1beta is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease.","volume":"186","author":"Pathak","year":"2011","journal-title":"J. Immunol."},{"key":"B215","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157488412803305821","article-title":"An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases.","volume":"7","author":"Pazyar","year":"2012","journal-title":"Curr. Clin. Pharmacol."},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00363","article-title":"IL-1beta inhibition in cardiovascular complications associated to diabetes mellitus.","volume":"8","author":"Peiro","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/art.24174","article-title":"Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?","volume":"60","author":"Picco","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B218","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1073\/pnas.041611398","article-title":"Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta.","volume":"98","author":"Pomerantz","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B219","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(87)91854-X","article-title":"Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis.","volume":"2","author":"Prieur","year":"1987","journal-title":"Lancet"},{"key":"B220","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2013-203682","article-title":"Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations.","volume":"72","author":"Primdahl","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"B221","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.berh.2011.10.017","article-title":"Miscellaneous non-inflammatory musculoskeletal conditions blau syndrome.","volume":"25","author":"Punzi","year":"2011","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"B222","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B223","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jbspin.2010.09.014","article-title":"Adult-onset still\u2019s disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra.","volume":"78","author":"Raffeiner","year":"2011","journal-title":"Joint Bone Spine"},{"key":"B224","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/PCC.0000000000000078","article-title":"Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically ill children\u2217.","volume":"15","author":"Rajasekaran","year":"2014","journal-title":"Pediatr. Crit. Care Med."},{"key":"B225","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1056\/NEJMoa0809568","article-title":"An autoinflammatory disease due to homozygous deletion of the IL1RN locus.","volume":"360","author":"Reddy","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B227","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of c-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"B228","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00381-006-1280-3","article-title":"Hydrocephalus in CINCA syndrome treated with anakinra.","volume":"22","author":"Rigante","year":"2006","journal-title":"Childs Nerv. Syst."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.1463-1326.2012.01637.x","article-title":"Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.","volume":"14","author":"Rissanen","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"B230","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1158\/1078-0432.CCR-06-0121","article-title":"Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.","author":"Robertson","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B231","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1084\/jem.150.3.709","article-title":"Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen.","volume":"150","author":"Rosenwasser","year":"1979","journal-title":"J. Exp. Med."},{"key":"B232","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.1542\/peds.2010-2192","article-title":"Clinical, genetic, and therapeutic diversity in 2 patients with severe mevalonate kinase deficiency.","volume":"129","author":"Ruiz Gomez","year":"2012","journal-title":"Pediatrics"},{"key":"B233","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/art.33342","article-title":"A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.","volume":"64","author":"Ruperto","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B234","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jaci.2007.09.021","article-title":"IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission.","volume":"121","author":"Ryan","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"B235","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/ard.2005.038091","article-title":"Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism.","volume":"65","author":"Rynne","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182700cc1","article-title":"Chronic recurrent multifocal osteomyelitis and deficiency of interleukin-1-receptor antagonist.","volume":"32","author":"Sakran","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B237","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2009.126185","article-title":"Variable expression and treatment of PAPA syndrome.","volume":"70","author":"Schellevis","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"B238","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","article-title":"Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies.","volume":"66","author":"Schulert","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"B239","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.jccase.2011.07.003","article-title":"A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis.","volume":"4","author":"Scott","year":"2011","journal-title":"J. Cardiol. Cases"},{"key":"B240","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4049\/jimmunol.139.5.1546","article-title":"A urine inhibitor of interleukin 1 activity that blocks ligand binding.","volume":"139","author":"Seckinger","year":"1987","journal-title":"J. Immunol."},{"key":"B241","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pediatrneurol.2008.10.004","article-title":"Febrile seizures: interleukin 1beta and interleukin-1 receptor antagonist polymorphisms.","volume":"40","author":"Serdaroglu","year":"2009","journal-title":"Pediatr. Neurol."},{"key":"B242","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/RHU.0b013e31812e00a1","article-title":"Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra).","volume":"13","author":"Settas","year":"2007","journal-title":"J. Clin. Rheumatol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial.","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit. Care Med."},{"key":"B244","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.P4.346","article-title":"Anakinra (IL-1 blockade) use in children with suspected fires: a single institution experience.","volume":"90","author":"Shukla","year":"2018","journal-title":"Neurology"},{"key":"B245","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes.","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B246","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.amjmed.2004.02.039","article-title":"Beneficial response to interleukin-1 receptor antagonist in TRAPS.","volume":"117","author":"Simon","year":"2004","journal-title":"Am. J. Med."},{"key":"B247","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1590\/S1516-31802010000500013","article-title":"Biologics for rheumatoid arthritis: an overview of cochrane reviews.","volume":"128","author":"Singh","year":"2010","journal-title":"Sao Paulo Med. J."},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-1","article-title":"The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial.","volume":"11","author":"Singh","year":"2014","journal-title":"J. Neuroinflammation"},{"key":"B249","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.2337\/dc12-1835","article-title":"Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes.","volume":"36","author":"Sloan-Lancaster","year":"2013","journal-title":"Diabetes Care"},{"key":"B250","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement.","volume":"36","author":"Solovic","year":"2011","journal-title":"Eur. Respir. J."},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4095-1","article-title":"Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.","author":"Sonmez","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00296-009-1169-z","article-title":"Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus?","volume":"31","author":"Sparsa","year":"2012","journal-title":"Rheumatol. Int."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/ndt\/gfr528","article-title":"Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial mediterranean fever complicated with amyloidosis and renal failure.","volume":"27","author":"Stankovic Stojanovic","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"B254","first-page":"161","article-title":"Muckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss.","volume":"9","author":"Stew","year":"2013","journal-title":"B-ENT"},{"key":"B255","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cmet.2010.11.011","article-title":"The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity.","volume":"12","author":"Stienstra","year":"2011","journal-title":"Cell Metab."},{"key":"B256","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/BOR.0b013e328349c3b1","article-title":"Hyper-IgD syndrome or mevalonate kinase deficiency.","volume":"23","author":"Stoffels","year":"2011","journal-title":"Curr. Opin. Rheumatol."},{"key":"B257","doi-asserted-by":"publisher","first-page":"7148","DOI":"10.1073\/pnas.1103681108","article-title":"Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade.","volume":"108","author":"Stojanov","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B258","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/09680519050110020301","article-title":"Interleukin-18 does not modulate the acute-phase response.","volume":"11","author":"Stuyt","year":"2005","journal-title":"J. Endotoxin. Res."},{"key":"B259","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1182\/blood-2010-08-300046","article-title":"Gene expression profiling of peripheral blood mononuclear cells from children with active hemophagocytic lymphohistiocytosis.","volume":"117","author":"Sumegi","year":"2011","journal-title":"Blood"},{"key":"B260","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1212\/01.wnl.0000263217.36439.da","article-title":"Inflammatory markers and the risk of Alzheimer disease: the Framingham Study.","volume":"68","author":"Tan","year":"2007","journal-title":"Neurology"},{"key":"B261","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.4049\/jimmunol.150.10.4687","article-title":"Induction of circulating IL-1 receptor antagonist by IFN treatment.","volume":"150","author":"Tilg","year":"1993","journal-title":"J. Immunol."},{"key":"B262","doi-asserted-by":"publisher","first-page":"H1025","DOI":"10.1152\/ajpheart.00795.2013","article-title":"Interleukin-18 mediates interleukin-1-induced cardiac dysfunction.","volume":"306","author":"Toldo","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1113\/expphysiol.2012.069831","article-title":"Interleukin-1beta blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse.","volume":"98","author":"Toldo","year":"2013","journal-title":"Exp. Physiol."},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01233","article-title":"Treating heart inflammation with interleukin-1 blockade in a case of erdheim-chester disease.","volume":"9","author":"Tomelleri","year":"2018","journal-title":"Front. Immunol."},{"key":"B265","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial.","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol."},{"key":"B266","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.seizure.2013.03.004","article-title":"Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures.","volume":"22","author":"Uludag","year":"2013","journal-title":"Seizure"},{"key":"B267","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.seizure.2015.01.009","article-title":"IL-1beta, IL-6 and IL1Ra levels in temporal lobe epilepsy.","volume":"26","author":"Uludag","year":"2015","journal-title":"Seizure"},{"key":"B268","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1172\/JCI76503","article-title":"Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease.","volume":"124","author":"Vambutas","year":"2014","journal-title":"J. Clin. Invest."},{"key":"B269","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1210\/jc.2010-2992","article-title":"Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study.","volume":"96","author":"van Asseldonk","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00167","article-title":"New Insights in the immunobiology of IL-1 family members.","volume":"4","author":"van de Veerdonk","year":"2013","journal-title":"Front. Immunol."},{"key":"B271","article-title":"Anakinra for the inflammatory complications of chronic granulomatous disease.","volume":"69","author":"van de Veerdonk","year":"2011","journal-title":"Neth. J. Med."},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2015.00004","article-title":"Ebola virus disease has features of hemophagocytic lymphohistiocytosis syndrome.","volume":"2","author":"van der Ven","year":"2015","journal-title":"Front. Med."},{"key":"B273","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/FJC.0000000000000378","article-title":"Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study.","volume":"67","author":"Van Tassell","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure.","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLoS One"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART.","volume":"10","author":"Van Tassell","year":"2017","journal-title":"Circ. Heart Fail."},{"key":"B276","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B277","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.bbi.2011.03.018","article-title":"IL-1 receptor\/toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures.","volume":"25","author":"Vezzani","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00380","article-title":"A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study.","volume":"7","author":"Vitale","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B279","doi-asserted-by":"publisher","first-page":"E46","DOI":"10.1002\/pbc.24480","article-title":"Cytokine profiles in children with primary epstein-barr virus infection.","volume":"60","author":"Wada","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"B280","first-page":"130","article-title":"A severe case of adult onset Stills isease with myopericarditis, resistant to treatment with tocilizumab but responsive to anakinra.","volume":"84","author":"Waghmare","year":"2015","journal-title":"Ulster Med. J."},{"key":"B281","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2011-200743","article-title":"Anakinra treatment of SAPHO syndrome: short-term results of an open study.","volume":"71","author":"Wendling","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B282","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","article-title":"Successful treatment of severe hidradenitis suppurativa with anakinra.","volume":"149","author":"Zarchi","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B283","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/annrheumdis-2012-202380","article-title":"A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder.","volume":"72","author":"Zufferey","year":"2013","journal-title":"Ann. Rheum. Dis."}],"updated-by":[{"DOI":"10.3389\/fphar.2019.00148","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T00:00:00Z","timestamp":1552003200000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:56:43Z","timestamp":1775260603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":285,"alternative-id":["10.3389\/fphar.2018.01157"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01157","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"article-number":"1157"}}